Business ❯ Pharmaceutical Industry

Drug Pricing Strategies

Market Competition Market Impact Negotiations Market Dynamics Market Analysis 340B Program Impact Direct to Consumer Sales Direct-to-Consumer Sales AstraZeneca Medicare and Medicaid Consumer Pricing Government Programs Negotiation Processes Medicaid Pricing Discount Programs Medicare Drug Negotiations Investment in Research Market Access International Pricing Government Regulations

Medicare’s First Negotiated Drug Prices Take Effect Jan. 1, Cutting 2026 Costs

AARP projects roughly 50% lower out-of-pocket spending in stand-alone Part D plans with CMS estimating $1.5 billion in enrollee savings.

CMS Launches ‘Generous’ Pilot to Tie Medicaid Drug Prices to International Benchmarks

Senators Edge Toward 340B Overhaul as CBO Warns on Costs and HRSA Plans 2026 Rebate Pilot